Living with CML can be challenging. Fortunately, these advances in CML treatment offer hope beyond daily pills.

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

The Congress of Neurological Surgeons (CNS) has updated its guidelines on using emerging therapies to treat metastatic brain ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined pipeline and ...